KRAS and neoplasm: Additionally, inactivating mutations or deletion of EZH2 have been identified in several types of tumor, such as Kras-driven lung adenocarcinoma and T cell precursor acute lymphoblastic leukemia, suggesting the tumor-suppressive effect of EZH2 in certain contexts (51, 52).